Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on LinkedIn:
”ASCO26 is almost here.
Here are just a few of the lung cancer abstracts I’ll be watching closely this year!”
1.Title: Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.
Authors: Jonathan W. Goldman, Xuening Yang, Maximilian Hochmair, Lin Wu, Hye Ryun Kim, Luis G. Paz-Ares, Damian T. Rieke, Melissa L. Johnson, James Chih Hsin Yang, Masahiro Tsuboi, Benjamin Besse, Nivedita Sharma, Patricia H. Maeda, Patrick Peterson, Bente Frimodt-Moller, Yi Yang, Alexander E. Drilon, Yi-Long Wu
Read the Full Abstract.
2.Title: Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ nonsmall cell lung cancer: 7-year update from the phase 3 CROWN study.
Authors: Tony S. Mok, Benjamin J. Solomon, Enriqueta Felip, Todd M. Bauer, Geoffrey Liu, Yasushi Goto, Yi-Long Wu, Ross A. Soo, Julien Mazieres, Filippo de Marinis, Dong-Wan Kim, I-Ming Wang, Jolanda Paolini, Anna Polli, Nada Rifi, Francesca Toffalorio, Alice T. Shaw
Read the Full Abstract.
3.Title: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
Authors: Chen Zhiwei, Fang Yang, Yongzhong Luo, Longhua Sun, Lin Wu, Zhengxiang Han, Yun Fan, Yanqiu Zhao, XingYa Li, Haipeng Xu, Xiangjiao Meng, Ying Liu, Zhiye Zhang, Hui Luo, Qin Shi, Xuelei Ma, Xuezhen Ma, Zhongmin Zhang, Michelle Y. Xia, Shun Lu
Read the Full Abstract.
4.Title: Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial.
Authors: Bjorn H. Gronberg, Daphne W. Dumoulin, Kersti Oselin, Luigi De Petris, Kirill Neumann, Tesfaye Madebo, Marianne Aanerud, Tarje O. Halvorsen, Johan Isaksson, Maria M. Bjaanæs, Daniel Heinrich, Odd Terje Brustugun, Atle Totland, Siv Gyda Aanes, Øyvind Yksnøy, Andreas Hallqvist, Orvar Gunnarsson, Terje Skraastad, Emelie Gezelius, Kristin T. Killingberg
Read the Full Abstract.
5.Title: Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
Authors: Giannis S. Mountzios, Byoung Chul Cho, Phil Lammers, Longhua Sun, Surein Arulananda, Fiona H. Blackhall, Tatsuya Yoshida, Myung-Ju Ahn, Salman R. Punekar, Bo Zhu, Tudor-Eliade Ciuleanu, Julien Mazieres, Antonio Lugini, Pedro Rocha, Ippokratis Korantzis, Martin Schuler, Wei Shi, Ali Hamidi, Diana Gauto, Charles M. Rudin
Read the Full Abstract.
6.Title: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.
Authors: Ferdinandos Skoulidis, Hossein Borghaei, Edward B. Garon, Ticiana Leal, Jacob Kaufman, Stephen V. Liu, Eric S. Nadler, Sandip Pravin Patel, Solange Peters, Biagio Ricciuti, Tarek Mekhail, Ajeet Gajra, Eric C. McGary, Vu Phan, James Stevenson, Richard Lynen, Ugochinyere Emeribe, Aida Myftiu, Ashish Gautam, John V. Heymach
Read the Full Abstract.
7.Title: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
Authors: John V. Heymach, Geoffrey Liu, Ligang Xing, Laurent Greillier, John Thomas, Ozan Yazici, Meili Sun, Yun Fan, Chengzhi Zhou, Mengzhao Wang, Regan M. Memmott, Dariusz Kowalski, Catherine A. Shu, Elaine Shum, Elvire Pons Tostivint, Federica Bertolini, Gonzalo Fernandez Hinojal, Lorenzo Antonuzzo, Yiman Wang, Caicun Zhou
Read the Full Abstract.
Other Articles Featuring Eric Singhi On OncoDaily.